Crude and adjusted HRs for anaemia among patients with prostate cancer during a 3-year follow-up period stratified by the duration of ADT
| Presence of iron-deficiency anaemia | Patients receiving short-term ADT (n=3631) * | Patients receiving long-term ADT (n=3634) * | Patients not receiving ADT (n=3631) |
| Three-year follow-up period | |||
| Incidence rate per 100 person-years (95% CI) | 2.24 (1.87 to 2.62) | 1.25 (1.02 to 1.48) | 1.01 (0.78 to 1.25) |
| Crude HR (95% CI) | 2.19 (1.64 to 2.92) | 1.25 (0.93 to 1.69) | 1.00 |
| Adjusted HR (95% CI)†‡ | 2.20 (1.64 to 2.94) | 1.22 (0.90 to 1.65) | 1.00 |
| Adjusted HR (95% CI)†§ | 2.06 (1.53 to 2.76) | 1.23 (0.91 to 1.66) | 1.00 |
*We categorised the patients receiving ADT into two levels according to the median duration of ADT use (144 days).
†Using a Cox proportional regression with data censored if individuals died during the 3-year follow-up period;.
‡Adjustments were made for patients’ geographic location, monthly income, urbanisation level, age and incidence of hyperlipidaemia, diabetes, hypertension, coronary heart disease and inflammatory bowel disease.
§Adjustments were made for patients’ geographic location, monthly income, urbanisation level, age and incidence of hyperlipidaemia, diabetes, hypertension, coronary heart disease, inflammatory bowel disease, other cancers and gastrointestinal bleeding.
ADT, androgen deprivation therapy.